Senseonics Holdings Inc (SENS)
Senseonics Holdings Inc is a commercial-stage medical technology company focused on developing and manufacturing continuous glucose monitoring systems for people with diabetes in the United States and internationally. Its Eversense product family includes Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems designed to track glucose levels using an under-the-skin sensor, a removable rechargeable smart transmitter, and a mobile app for real-time monitoring and diabetes management. The company works with healthcare providers and patients through distributors and strategic fulfillment partners. Founded in 1996, Senseonics is headquartered in Germantown, Maryland, and its common stock is listed on the NASDAQ under the symbol SENS.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SENS
|
$10.41
|
3.5% Upside
|
Fair
|
$14.20
|
41.2% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 10, 2026
|
5.9x
|
11.0x
|
531.9 M
|
452.1 M
|
10.8%
|
83.8%
|
-5.8
|
89.7%
|
